TABLE 2. Synoptic table containing the characteristics of the included studies.
| Citation | Title | General study data |
|---|---|---|
| Liu et al., 202511 | Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells | Study type: Preclinical experimental study |
| Population: Not described | ||
| Follow-up time: 14 days | ||
| Type and dose of GLP studied: GLP-1, the dose was 0.5 mg/kg administered subcutaneously (SC) | ||
| Type of IBD studied: Crohn’s disease | ||
| Wang, Zhang, Zhang 202312 | The alleviating effect and mechanism of GLP-1 on ulcerative colitis | Study type: Preclinical experimental study |
| Population: 48 mice | ||
| Follow-up time: 7 days | ||
| Type and dose of GLP studied: GLP-1, dose 0.2 mg/kg intraperitoneally (IP) | ||
| Type of IBD studied: Ulcerative colitis | ||
| Zatorski et al., 20198 | Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives | Study type: Integrative review |
| Population: Not described | ||
| Follow-up time: Not described | ||
| Type and dose of GLP studied: GLP-1 and GLP-2, varying doses | ||
| Type of IBD studied: Crohn’s disease and ulcerative colitis. | ||
| El-Jamal et al., 201415 | Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration | Study type: Preclinical experimental study |
| Population: Not described | ||
| Follow-up time: 10 days | ||
| Type and dose of GLP studied: GLP-2, the dose was 750 ng twice daily and 350 ng twice daily subcutaneously. | ||
| Type of IBD studied: Ulcerative colitis | ||
| Villumsen et al., 20214 | GLP-1 based therapies and disease course of inflammatory bowel disease | Study type: Retrospective cohort study |
| Population: 3751 participants | ||
| Follow-up time: Not described | ||
| Type and dose of GLP studied: GLP-1, dose not described | ||
| Type of IBD studied: Crohn’s disease and ulcerative colitis. | ||
| Pizzoferrato et al., 202216 | Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure | Study type: Integrative review |
| Population: Not described | ||
| Follow-up time: Not described | ||
| Type and dose of GLP studied: GLP-2, the dose was 0.05 mg/kg/day and 0.10 mg/kg/day, via daily subcutaneous injection | ||
| Type of IBD studied: Crohn’s disease | ||
| Buchman et al,. 201017 | Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn’s disease | Study type: Randomized controlled clinical trial |
| Population: 71 participants | ||
| Follow-up time: 8 weeks | ||
| Type and dose of GLP studied: GLP-2, at a dose of 0.05, 0.10, or 0.20 mg/kg/day | ||
| Type of IBD studied: Crohn’s disease | ||
| Xiao et al,. 200018 | Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease | Study type: Cross-sectional observational study |
| Population: 546 | ||
| Follow-up time: Not described | ||
| Type and dose of GLP studied: GLP-2, dose not described | ||
| Type of IBD studied: Crohn’s disease and Ulcerative Colitis | ||
| St-Pierre et al., 202413 | Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease | Study type: Retrospective cohort study |
| Population: 36 patients | ||
| Follow-up time: 3 years | ||
| Type and dose of GLP studied: GLP-1, dose not described | ||
| Type of IBD studied: Crohn’s disease and ulcerative colitis | ||
| Belinchon et al., 202514 | Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease | Study type: Retrospective cohort study |
| Population: 16 patients | ||
| Follow-up time: 6 months | ||
| Type and dose of GLP studied: GLP-1, at a dose of 1 mg semglutide and 3 mg liraglutide | ||
| Type of IBD studied: Crohn’s disease and ulcerative colitis |
SC: subcutaneous. IP: intraperitoneal.